Zenagamtide (amycretin)
Zenagamtide, formerly called amycretin, is an investigational Novo Nordisk medicine that activates GLP-1 and amylin receptors from a single molecule. It has been tested as a weekly injection and a daily pill. It is not approved.
Also searched as: amycretin, NNC0487-0111.
Educational information. This page does not give dosing instructions or tell you what to take. Ask a prescriber about your own care.
In plain English
Zenagamtide was known as amycretin until recently. Papers and trial records from 2026 use the new name. One molecule activates both the GLP-1 receptor (the one semaglutide targets) and the amylin receptor, so one injection or pill does the work of a combination like CagriSema.
The first obesity study was small. At one U.S. site, 125 adults lost an estimated 24.3% (60 mg weekly, 36 weeks) and 22.0% (20 mg weekly) of body weight, versus about 1% to 2% on placebo. Many people dropped out of that study, so treat it as a first look.
Novo Nordisk is running phase 3 trials called AMAZE for obesity, including a head-to-head against semaglutide, and a daily oral version. Two phase 2 diabetes trials in 2026 also found lower blood sugar. It is not approved.
Brand names and products
A generic name identifies the drug itself. A brand name identifies one company's product. One drug can come in several products with different forms and approved uses, so the brand name often tells you more about what a prescription is for.
No brand name is recorded for this medicine because there is no approved product.
Approved and investigational. Every use of zenagamtide is investigational. There is no approved product.
How it works
Zenagamtide is a single peptide that activates GLP-1, amylin and calcitonin receptors. GLP-1 lowers appetite and helps insulin release after meals. Amylin slows stomach emptying and promotes fullness. Both an injectable and an oral version are in development.
Forms and approval status
| Form | How it is taken | U.S. status |
|---|---|---|
| Zenagamtide injection (investigational) | Once weekly in trials. Available only inside clinical trials. | Not approved. Novo Nordisk's phase 3 program includes AMAZE 7, a trial against semaglutide in about 650 people that started in September 2026, plus other obesity and diabetes trials. |
| Zenagamtide tablet (investigational) | Once daily in trials. Available only inside clinical trials. | Not approved. AMAZE 9, a phase 3 trial of the daily tablet in about 950 people with obesity, started in August 2026. |
What the trials found
These are group averages from published trials in adults without diabetes unless stated. See how to read trial numbers before comparing.
Zenagamtide (amycretin) phase 1b/2a
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 125 adults aged 18 to 55 with a BMI of 27.0 to 39.9, at one research center in San Antonio, Texas
- Length
- 36 weeks
- Compared with
- Placebo. Several small groups: once-weekly injections raised to 60 mg or 20 mg over 36 weeks, 5 mg over 28 weeks, or 1.25 mg over 20 weeks
- What was measured
- Estimated average change in body weight at the end of each part
- Analysis approach
- Estimated mean change from the study's statistical model. A large number of participants left the study early
- Other results
- 5 mg for 28 weeks: -16.2% vs +2.3% placebo. 1.25 mg for 20 weeks: -9.7% vs +2.0% placebo. The 20 mg placebo group changed by +1.9%.
- Safety
- Stomach and gut side effects were the most common, mostly mild to moderate. Many people withdrew, mostly for reasons the authors said were unrelated to side effects.
- Limits
- Early-stage study with 101 people on the medicine split across several groups, at one site, with many dropouts. The 60 mg amount is higher than the largest amount (40 mg) later tested in the phase 2 diabetes trial, so these figures should be read as a first look only. Funded by the manufacturer. Group averages do not predict one person's result.
Sources: Dahl K 2025
Safety
No FDA label exists for this medicine yet. The information below comes from published trial reports. The points below are a summary and may be incomplete.
Boxed warning and label notes
- Zenagamtide injection (investigational): Not applicable. Not approved.
- Zenagamtide tablet (investigational): Not applicable. Not approved.
Warnings labels describe
- Not approved, so no official label exists. Safety information comes from trial reports.
- The first obesity study was small, at one site, and many participants left early.
Most common in trials
- Nausea, vomiting, diarrhea and other stomach and gut side effects, mostly mild to moderate
Less common but serious
- In the weekly-injection diabetes trial, 8% of participants reported serious adverse events, including 3 of 37 on placebo, with no deaths. In the oral diabetes trial, 4% reported them, with none on placebo and no deaths.
What is still unknown
- Phase 3 results. The trials started in late 2026, and primary completion dates run into 2028 and 2029.
- How large the weight loss is in a bigger, longer, more typical trial. The first study was small.
- How it compares with semaglutide and CagriSema in a head-to-head trial. AMAZE 7 is testing the semaglutide comparison.
- How well the daily tablet absorbs and how its weight loss compares with the injection.
- Heart-outcome results. A large cardiovascular trial is registered but not yet recruiting.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Sources
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study Dahl K, et al. Lancet. 2025;406(10499):149-162. PMID 40550231. Funding: Novo Nordisk. Journal article
- Efficacy and safety of once-weekly subcutaneous zenagamtide in type 2 diabetes: a phase 2 trial Mora P, et al. Lancet. 2026;408(10555):621-635. PMID 42532080. Funding: Novo Nordisk. Journal article
- AMAZE 7: zenagamtide compared with semaglutide in obesity (NCT07668414) ClinicalTrials.gov identifier NCT07668414. Sponsor: Novo Nordisk. Trial registry
- ClinicalTrials.gov U.S. National Library of Medicine. Trial registry
- Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes: a phase 2 trial Mora P, et al. Lancet. 2026;408(10555):607-620. PMID 42532079. Funding: Novo Nordisk. Journal article
- AMAZE 9: oral zenagamtide in obesity (NCT07720271) ClinicalTrials.gov identifier NCT07720271. Sponsor: Novo Nordisk. Trial registry